Empagliflozin inhibits autophagy and mitigates airway inflammation and remodelling in mice with ovalbumin-induced allergic asthma

Hussein, Noha A; Gawad, Hala S Abdel; Maklad, Hala M; El‐Fakharany, Esmail M.; Samy, Doaa M.

doi:10.1016/j.ejphar.2023.175701

Cited by 5 publications

(1 citation statement)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preliminary findings are pointing toward encouraging results. 26 Notably, two clinical trials incorporated empagliflozin to report its influence on liver lipid content, energy metabolism, and overall body composition in recently diagnosed T2DM patients.…”

Section: Resultsmentioning

confidence: 99%

Exploring Promising Therapies for Non-Alcoholic Fatty Liver Disease: A ClinicalTrials.gov Analysis

Hegazi,

Alalalmeh,

Shahwan

et al. 2024

DMSO

View full text Add to dashboard Cite

Background Non-alcoholic fatty liver disease (NAFLD) is a common disease and has been increasing in recent years. To date, no FDA-approved drug specifically targets NAFLD. Methods The terms “Non-alcoholic Fatty Liver Disease” and “NAFLD” were used in a search of ClinicalTrials.gov on August 24, 2023. Two evaluators independently examined the trials using predetermined eligibility criteria. Studies had to be interventional, NAFLD focused, in Phase IV, and completed to be eligible for this review. Results The ClinicalTrials.gov database was searched for trials examining pharmacotherapeutics in NAFLD. The search revealed 1364 trials, with 31 meeting the inclusion criteria. Out of these, 19 were finalized for evaluation. The dominant intervention model was Parallel. The most prevalent studies were in Korea (26.3%) and China (21.1%). The most common intervention was metformin (12.1%), with others like Exenatide and Pioglitazone accounting for 9.1%. Conclusion Therapeutics used to manage NAFLD are limited. However, various medications offer potential benefits. Further investigations are definitely warranted.

show abstract

Section: Resultsmentioning

confidence: 99%